← Eichor
Study identifier: NCT06448923 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Cannabidiol After Multi-Trauma for Pain and Opioid Therapy

Condition: Fracture  ·  Sponsor: Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal

PhasePhase 2
Planned participants225
Who can joinAll sexes, 18 Years to 70 Years
Healthy volunteersNo

About this study

The aim of this project is to investigate the therapeutic potential and safety of acute Cannabidiol (CBD) treatment on longitudinal pain symptoms, and to assess potential interactions with pain mediators including opioids and sex on CBD treatment response. To this end, this research protocol proposes a comprehensive translational approach including a placebo-controlled randomized clinical trial comparing two daily doses of CBD treatment administered for one month on pain relief. This study will also compare intervention conditions on inflammation markers, participant quality of life, sleep quality, depression, anxiety, cognition and orthopaedic function.

This description comes directly from the study's public registry record.

Talk to the study team

Louis De Beaumont, PhD  ·  514-338-2222  ·  louis.de.beaumont@umontreal.ca

Always discuss trial participation with your own doctor first.

Locations (1)

Hôpital Sacré-Coeur de MontréalMontreal, Quebec, CanadaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06448923